Recurrent Respiratory Papillomatosis
23
5
6
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
4.3%
1 terminated out of 23 trials
90.9%
+4.4% vs benchmark
17%
4 trials in Phase 3/4
70%
7 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (23)
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
Merck IIT: RRP Pembro and Lenvatinib
Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients
Zopa Retreatment and Vector Shedding in Adults With RRP
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
M7824 in People With Recurrent Respiratory Papillomatosis
Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)
Avelumab for People With Recurrent Respiratory Papillomatosis
Use of Cidofovir for Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis and Extraesophageal Reflux
Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis
Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions
Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children
Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis